scholarly journals Genetic and epigenetic pathways in Down syndrome: Insights to the brain and immune system from humans and mouse models

Author(s):  
Y. Eugene Yu ◽  
Zhuo Xing ◽  
Catherine Do ◽  
Annie Pao ◽  
Eun Joon Lee ◽  
...  
2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Eilam Yeini ◽  
Paula Ofek ◽  
Sabina Pozzi ◽  
Nitzan Albeck ◽  
Dikla Ben-Shushan ◽  
...  

AbstractGlioblastoma (GB) is a highly invasive type of brain cancer exhibiting poor prognosis. As such, its microenvironment plays a crucial role in its progression. Among the brain stromal cells, the microglia were shown to facilitate GB invasion and immunosuppression. However, the reciprocal mechanisms by which GB cells alter microglia/macrophages behavior are not fully understood. We propose that these mechanisms involve adhesion molecules such as the Selectins family. These proteins are involved in immune modulation and cancer immunity. We show that P-selectin mediates microglia-enhanced GB proliferation and invasion by altering microglia/macrophages activation state. We demonstrate these findings by pharmacological and molecular inhibition of P-selectin which leads to reduced tumor growth and increased survival in GB mouse models. Our work sheds light on tumor-associated microglia/macrophage function and the mechanisms by which GB cells suppress the immune system and invade the brain, paving the way to exploit P-selectin as a target for GB therapy.


2019 ◽  
Vol 21 (1) ◽  
pp. 21-25 ◽  

Emerging results support the concept that Alzheimer disease (AD) and age-related dementia are affected by the ability of the immune system to contain the brain's pathology. Accordingly, well-controlled boosting, rather than suppression of systemic immunity, has been suggested as a new approach to modify disease pathology without directly targeting any of the brain's disease hallmarks. Here, we provide a short review of the mechanisms orchestrating the cross-talk between the brain and the immune system. We then discuss how immune checkpoint blockade directed against the PD-1/PD-L1 pathways could be developed as an immunotherapeutic approach to combat this disease using a regimen that will address the needs to combat AD.


2019 ◽  
Vol 21 (1) ◽  
pp. 21-25 ◽  

Emerging results support the concept that Alzheimer disease (AD) and age-related dementia are affected by the ability of the immune system to contain the brain’s pathology. Accordingly, well-controlled boosting, rather than suppression of systemic immunity, has been suggested as a new approach to modify disease pathology without directly targeting any of the brain’s disease hallmarks. Here, we provide a short review of the mechanisms orchestrating the cross-talk between the brain and the immune system. We then discuss how immune checkpoint blockade directed against the PD-1/PD-L1 pathways could be developed as an immunotherapeutic approach to combat this disease using a regimen that will address the needs to combat AD.


2021 ◽  
Vol 535 ◽  
pp. 87-92
Author(s):  
Ryohei Shimizu ◽  
Keiichi Ishihara ◽  
Eri Kawashita ◽  
Haruhiko Sago ◽  
Kazuhiro Yamakawa ◽  
...  

Cell ◽  
1986 ◽  
Vol 47 (3) ◽  
pp. 333-348 ◽  
Author(s):  
Paul Jay Maddon ◽  
Angus G. Dalgleish ◽  
J.Steven McDougal ◽  
Paul R. Clapham ◽  
Robin A. Weiss ◽  
...  

2013 ◽  
Vol 35 (4) ◽  
pp. 589-593
Author(s):  
Bin Yu ◽  
Jing Kong ◽  
Baoling Xing ◽  
Ziqiang Zhu ◽  
Bin Zhang ◽  
...  
Keyword(s):  

2018 ◽  
Vol 215 (11) ◽  
pp. 2702-2704 ◽  
Author(s):  
Aleksandra Deczkowska ◽  
Michal Schwartz

Immune cells patrol the brain and can support its function, but can we modulate brain–immune communication to fight neurological diseases? Here, we briefly discuss the mechanisms orchestrating the cross-talk between the brain and the immune system and describe how targeting this interaction in a well-controlled manner could be developed as a universal therapeutic approach to treat neurodegeneration.


Sign in / Sign up

Export Citation Format

Share Document